Article

Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization study

2020-10-21

Abstract excerpt

<h4>Background</h4> Exenatide is a glucagon-like peptide 1 receptor (GLP1R) agonist used in type 2 diabetes mellitus that has shown promise for Parkinson’s disease in a phase II clinical trial. Drugs with genetic evidence are more likely to be successful in clinical trials. In this study we investigated whether the genetic technique Mendelian randomization (MR) can “rediscover” the effects of exenatide on diabetes...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8c4b5f2b-c9ee-52cd-af0c-63f9b28ee8d7
DOI: 10.1101/2020.10.20.20215855

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Predicting the efficacy of exenatide in Parkinson’s disease using genetics – a Mendelian randomization studyDOI 10.1101/2020.10.20.20215855Read

The Parkinson's Disease Mendelian Randomization Research Portal.Semantic proximity Read

Finding drug targeting mechanisms with genetic evidence for Parkinson’s diseaseSemantic proximity Read

Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.Semantic proximity Read

Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s diseaseSemantic proximity Read

Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomizationSemantic proximity Read

Causal association between Parkinson's disease with multiple cancers: a Mendelian randomization studySemantic proximity Read

<scp>M</scp> endelian <scp>R</scp> andomization — the <scp>K</scp> ey to <scp>U</scp> nderstanding <scp>A</scp> spects of <scp>P</scp> arkinson's <scp>D</scp> isease <scp>C</scp> ausation?Semantic proximity Read

GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity Read

Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study.Semantic proximity Read

Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomization studySemantic proximity Read

Systematic genome-wide Mendelian randomization reveals the causal links between miRNAs and Parkinson’s diseaseSemantic proximity Read

Mendelian Randomization Analysis Reveals No Causal Relationship Between Plasma α-Synuclein and Parkinson's Disease.Semantic proximity Read